Further, RNA-sequencing data also show that USP22 mRNA expression is more frequently reduced in ovarian, esophagus, breast, colorectal, pancreatic and stomach cancers (Figure 3C) [37]. This evidence concerns the gene USP22 and gastric neoplasm.